Reader-Supported · Editorially Reviewed
Evidence Watch · Peer-reviewed East Asian trial

12.1% Average Loss With Semaglutide at 44 Weeks

STEP 7 studied weekly semaglutide 2.4 mg in a predominantly East Asian population with overweight or obesity. Its 44-week result is an average under the trial's eligibility, titration, lifestyle, and follow-up conditions—not a prediction for a particular person or program.

Last reviewed September 2026
1 study cited
The Lancet Diabetes & EndocrinologyPhase 3a, multicenter, double-blind, randomized, placebo-controlled trial44-week treatment period
The study result

At week 44, estimated mean body-weight change was −12.1% with semaglutide 2.4 mg and −3.6% with placebo.

The estimated treatment difference was −8.5 percentage points. At least 5% weight loss occurred in 85% of semaglutide participants and 31% of placebo participants. Gastrointestinal disorders were reported in 67% and 36%, respectively.

Compare programs

Turn the study result into a better program comparison

If this result prompts you to compare GLP-1 programs, focus on practical factors the trial did not test: available plans, clinician access, medication status, follow-up, public price terms, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.

01
WellMedr logo
WellMedr

From $49 – $129/mo · Editorial score 4.7/5

Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.

Semaglutide at WellMedr
02
Strut Health logo
Strut Health

From $149 – $399/mo · Editorial score 4.6/5

Semaglutide at Strut Health
03
Trimi logo
Trimi

From $99 – $125/mo · Editorial score 4.8/5

Tirzepatide at Trimi
04
Telos Rx logo
Telos Rx

From $49 – $399/mo · Editorial score 3.9/5

Tirzepatide at Telos Rx
05
HealthRx logo
HealthRx

From $99 – $209/mo · Editorial score 4.1/5

Semaglutide at HealthRx
06
Cielo Health logo
Cielo Health

From $115 – $299/mo · Editorial score 4.4/5

Tirzepatide at Cielo Health

We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology

Study details

Population
375 adults with overweight or obesity, with or without type 2 diabetes; 72% were enrolled in mainland China, with additional sites in South Korea, Hong Kong, and Brazil
Follow-up
44-week treatment period
Treatment comparison
Once-weekly subcutaneous semaglutide escalated to 2.4 mg compared with placebo, alongside a reduced-calorie diet and increased physical activity
Study design
Phase 3a, multicenter, double-blind, randomized, placebo-controlled trial
Care and plan considerations

A study result is not a personal treatment plan

The trial does not determine whether semaglutide is appropriate for an individual, what a provider can prescribe, or what insurance covers. It studied a specific weekly 2.4 mg injectable regimen, not oral semaglutide, higher-dose products, or telehealth programs. Those decisions require a licensed clinician and current prescribing information.

Compare semaglutide and tirzepatide programs

What this result does not show

  • The 44-week duration does not establish long-term weight maintenance, results after stopping treatment, or uncommon or late adverse effects.
  • The cohort was predominantly mainland Chinese and used WHO BMI thresholds, so results may not directly generalize to every population or care setting.
  • The trial compared semaglutide with placebo, not another active weight-management medicine or another clinical-support model.
  • It was not designed to compare telehealth providers, affordability, insurance coverage, pharmacy access, or individual treatment outcomes.
  • Novo Nordisk funded the study, and author disclosures are reported in the peer-reviewed article.
Not sure which provider fits you? Take the 30-second quiz
Answer 4 quick questions to get a personalized provider match
Continue reading

Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.

All study updates
Study & references

Primary peer-reviewed source

Mu et al., Lancet Diabetes & Endocrinology 2024 · STEP 7

Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.

Read the study at The Lancet Diabetes & Endocrinology